The signal from a spirometer is directly correlated with respiratory motion and is ideal for target respiratory motion tracking. However, its susceptibility to signal drift deters its application in radiotherapy. In this work, a few approaches are investigated to control spirometer signal drift for a Bernoulli-type spirometer. A method is presented for rapid daily calibration of the spirometer to obtain a flow sensitivity function. Daily calibration assures accurate airflow measurement and also reduces signal drift. Dynamic baseline adjustment further controls the signal drift. The accuracy of these techniques was studied and it was found that the spirometer is able to provide a long-term drift-free breathing signal. The tracking error is comprised of two components: calibration error and stochastic signal baseline variation error. The calibration error is very small ͑1% of 3 l͒ and therefore negligible. The stochastic baseline variation error can be as large as 20% of the normal breathing amplitude. In view of these uncertainties, the applications of spirometers in treatment techniques that rely on breathing monitoring are discussed. Spirometer-based monitoring is noted most suitable for deep inspiration breath-hold but less important for free breathing gating techniques.
Similar to conventional conformal radiotherapy, during lung tomotherapy, a motion margin has to be set for respiratory motion. Consequently, large volume of normal tissue is irradiated by intensive radiation. To solve this problem, we have developed a new motion mitigation method by incorporating target motion into treatment optimization. In this method, the delivery-breathing correlation is determined prior to treatment plan optimization. Beamlets are calculated by using the CT images at the corresponding breathing phases from a dynamic ͑four-dimensional͒ image sequence. With the displacement vector fields at different breathing phases, a set of deformed beamlets is obtained by mapping the dose to the primary phase. Optimization incorporating motion is then performed by using the deformed beamlets obtained by dose mapping. During treatment delivery, the same breathing-delivery correlation can be reproduced by instructing the patient to breathe following a visually displayed guiding cycle. This method was tested using a computer-simulated deformable phantom and a real lung case. Results show that treatment optimization incorporating motion achieved similar high dose conformality on a mobile target compared with static delivery. The residual motion effects due to imperfect breathing tracking were also analyzed.
The purpose of this study is to describe the comprehensive commissioning process and initial clinical experience of the Mevion S250 proton therapy system, a gantry‐mounted, single‐room proton therapy platform clinically implemented in the S. Lee Kling Proton Therapy Center at Barnes‐Jewish Hospital in St. Louis, MO, USA. The Mevion S250 system integrates a compact synchrocyclotron with a C‐inner gantry, an image guidance system and a 6D robotic couch into a beam delivery platform. We present our commissioning process and initial clinical experience, including i) CT calibration; ii) beam data acquisition and machine characteristics; iii) dosimetric commissioning of the treatment planning system; iv) validation through the Imaging and Radiation Oncology Core credentialing process, including irradiations on the spine, prostate, brain, and lung phantoms; v) evaluation of localization accuracy of the image guidance system; and vi) initial clinical experience. Clinically, the system operates well and has provided an excellent platform for the treatment of diseases with protons.PACS number(s): 87.55.ne, 87.56.bd
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.